Sign in
CompletedNo phase

Ferric Carboxymaltose Methemoglobinemia Study

Key facts

Who runs it
Ordu University
Where
Türkiye23 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
977 people enrolled
Started
14 Apr 2025
Ended
30 Sept 2025
Type of study
Observational, 2 groups
Treatments tested
  • Ferric Carboxymaltose (FCM)
Record updated
19 November 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • FCM Group:
  • Adults (≥18 years)
  • Presence of anemia (Hb <12 g/dl in women, <13 g/dl in men)
  • Low ferritin (<30 mcg/l)
  • Patients for whom FCM administration has been decided in routine medical care practice; Control Group:; Healthy adult (≥18 years) individuals who applied to the internal medicine outpatient clinic, who had no current or pre-existing chronic disease, who did not have anemia and iron deficiency (ferritin ≥30 mcg/L)

Who cannot take part

  • Use of drugs associated with methemoglobinemia (acetylsalicylic acid, dapsone, chloroquine, metoclopramide, benzocaine, lidocaine, prilocaine, rasburicase, primaquine, sulfonamide, nitric oxide)
  • Known methemoglobinemia-related diseases (Hb M disease, cytochrome b5 reductase deficiency, etc.)
  • Presence of advanced organ failure (Stage 4 and 5 chronic kidney disease, Child C cirrhosis, NYHA class 3 and 4 chronic heart failure, respiratory failure requiring oxygen supplementation and similar processes)
  • Presence of malignancy (with or without cure)
  • Presence of active infection (CRP > 5 mg/dL) and/or other acute disorder/disease
  • Those with B12 and/or folate deficiency
  • Those with Charlson Comorbidity Index ≥3
  • Pregnancy status

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Anemia that develops due to iron deficiency is called iron deficiency anemia. This common condition is treated with iron supplements taken either orally or given through an intravenous (IV) infusion. Ferric carboxymaltose (FCM) is one of the widely used, comparably newer IV iron preparations. Recently, several publications have raised the possibility that FCM may be associated with mild elevations in methemoglobin (metHb), a form of hemoglobin that cannot effectively deliver oxygen to tissues.

Read full original descriptionShow less

Methemoglobinemia is a known, though uncommon, side effect of some drugs. While usually mild and self-limiting, in certain cases it can become clinically significant or even life-threatening. This observational study is being conducted across multiple centers to better understand how often methemoglobinemia occurs after administration of FCM. As part of routine care, venous blood samples will be used to measure metHb levels in patients receiving FCM, and these results will be compared with those from individuals not exposed to the drug.

The 2 groups in the trial

  • FCM Group

    It will represent the group of patients who will be administered ferric carboxymaltose (FCM), i.e., the exposed group.

    Treatment: Ferric Carboxymaltose (FCM)

  • Control Group

    It will represent the control group of patients who do not receive FCM or any form of iron therapy, i.e., the unexposed group.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Estimation of the Incidence of Methemoglobinemia Associated With Ferric Carboxymaltose Administration
Record updated
19 November 2025